glp-1 drug liraglutide may protect against dementia Ozempic predecessor suggests potential for drugs in Alzheimer's in early trial Alzheiemer's: Can a GLP-1 drug

Liraglutide is a GLP-1 receptor agonist administered subcutaneously

Studies in patients with type 2 diabetes and obesity have demonstrated that the use of SGLT2 inhibitors, particularly empagliflozin, not only increases overall cancer risk but also significantly elevates the risk of bladder cancer [10, 108]

Before we talk about the association and connection between their use and the risk of thyroid cancer, lets take a step back and talk about some basics: What Are GLP-1 Agonists & Why Should You Care

In a study of 3,731 patients assigned to take either liraglutide or placebo, 63.2% of patients taking liraglutide lost at least 5% of their body weight and 33.1% of patients lost at least 10% of their body weight

North America leads with 50.14% share in 2024, supported by high diabetes prevalence and advanced treatment adoption

doi: 10.1007/s40262-015-0338-3 [DOI] [PubMed] [Google Scholar] 194.Tang CC, Lim J, Loo LS, Jung H, Konig M, Tham LS